Alex Bastian is the VP of Commercial Strategy of Memo Therapeutics AG and is an experienced commercial leader in the biotech sector. He was formerly VP of Commercial & Patient Access at AM-Pharma, where he led market access for an innovative in-hospital therapy for acute kidney injury. Alex has also held various senior roles in big pharma including Pfizer and Amgen in addition to small biotech with Galapagos and Incyte Corporation in both Europe and the US. He is completing a Doctor of Public Health at the Johns Hopkins Bloomberg School of Public Health, USA, has an MBA from IESE Business School in Barcelona, Spain and a bachelor’s degree from the University of Minnesota, USA.

Memo Therapeutics AG is a late-stage biotech company developing best-in-class therapeutic antibodies to transform the lives of patients with viral infections and cancer. Our lead program, potravitug, currently in Phase II development, is the most potent antibody ever tested in clinical trials to treat BK viremia in kidney transplant recipients. BK viremia can lead to nephropathy, loss of kidney function, as well as organ failure, rejection and death. Other programs consist of therapeutic antibodies focusing on novel oncology targets which we are developing both alone and in partnership.